Soligenix: Funding, Investors & Team (Sep 2026)
A late-stage biopharmaceutical business called Soligenix is dedicated to creating and marketing treatments for rare diseases when there is an unmet medical need. In order to treat cutaneous T-cell lymphoma, our Specialized BioTherapeutics business sector is creating and marketing HyBryteTM (SGX301, or synthetic hypericin), a revolutionary photodynamic therapy that uses secure visible light (CTCL) Regulational approval and initial commercialization of this therapy are being advanced in the US following the completion of a fruitful Phase 3 research.
Soligenix has raised $10.6M across 3 funding rounds on record, the most recent an undisclosed round of $8.5M announced in May 2023.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Soligenix Company Profile and Key Stats
Latest funding round on record: May 2023.
Soligenix Funding Rounds
Soligenix raised $900k in an undisclosed round announced in Jun 2021.
1.4 years later, an undisclosed round of $1.2M was announced in Nov 2022.
6 months later, an undisclosed round of $8.5M was announced in May 2023.
Soligenix Founders and Leadership Team
No contact details are on record for this team yet.
Soligenix Funding Compared to Other Biotechnology Startups
Soligenix's latest round of $8.5M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Soligenix in Biotechnology and Princeton
Companies Similar to Soligenix
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Soligenix Funding FAQs
What does Soligenix do?
A late-stage biopharmaceutical business called Soligenix is dedicated to creating and marketing treatments for rare diseases when there is an unmet medical need. In order to treat cutaneous T-cell lymphoma, our Specialized BioTherapeutics business sector is creating and marketing HyBryteTM (SGX301, or synthetic hypericin), a revolutionary photodynamic therapy that uses secure visible light (CTCL) Regulational approval and initial commercialization of this therapy are being advanced in the US following the completion of a fruitful Phase 3 research.
How much funding has Soligenix raised?
Soligenix has raised $10.6M across 3 rounds on record. The most recent is an undisclosed round of $8.5M announced in May 2023.
When did Soligenix last raise funding?
Soligenix's most recent funding round on record is an undisclosed round of $8.5M, announced in May 2023.
Who founded Soligenix?
FundedIQ lists Christopher J Schaber (Founder) at Soligenix.
Who is the CEO of Soligenix?
Christopher J. Schaber is listed as CEO at Soligenix.
Where is Soligenix headquartered?
Soligenix is based in Princeton, New Jersey, United States.
How many employees does Soligenix have?
Soligenix is in the 11-50 employee band.
How does Soligenix's funding compare to other Biotechnology startups?
Soligenix's latest round of $8.5M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Soligenix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Soligenix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.